Real-world treatment persistence in csDMARD-IR and bDMARD-IR patients with rheumatoid arthritis in Japan: A large claims database study
Modern Rheumatology · 2025
DOI: 10.1093/mr/roaf007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Tsutomu Takeuchi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Janus Kinase Inhibitors, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To investigate treatment persistence for biologic disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKis), including filgotinib, in Japanese patients with rheumatoid arthritis (RA) who have an inadequate response (IR) to conventional synthetic DMARDs (csDMARD-IR) and bDMARDs (bDMARD-IR), and to identify characteristics associated with treatment discontinuation.
Methods
We analyzed 2020–2023 health claims data from adults with RA who received ≥1 prescription for bDMARDs or JAKis during the study period and ≥1 prescription for csDMARDs over the previous 6 months. Persistence rates were estimated for the csDMARD-IR (patients naïve to bDMARDs/JAKis) and bDMARD-IR (patients switching to bDMARDs/JAKis from an initial bDMARD) cohorts using the Kaplan–Meier method.
Results
Overall, 7208 and 1581 patients were identified in the csDMARD-IR and bDMARD-IR cohorts, respectively. In the csDMARD-IR cohort, 1-year persistence rates were 59%–70% for JAKis (67% for filgotinib) and 53%–69% for bDMARDs. In the bDMARD-IR cohort, 1-year persistence rates were 57%–66% for JAKis (66% for filgotinib) and 19%–91% for bDMARDs. No clinical characteristics were consistently associated with the persistence of JAKi or bDMARD treatment.
Conclusions
Rates of persistence among patients taking JAKis, including filgotinib, were approximately 60% or higher in csDMARD-IR and bDMARD-IR cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
- Saitama Medical University, Saitama, Japan.
- Gilead Sciences, Inc., Foster City, CA, United States.
- Gilead Sciences, K.K., Tokyo, Japan.
Zitieren
APA
Takeuchi, T., Pfeifer, C., Zhong, Y., Piao, Y., Kaise, T., & Tani, M. (2025). Real-world treatment persistence in csDMARD-IR and bDMARD-IR patients with rheumatoid arthritis in Japan: A large claims database study. Modern Rheumatology. https://doi.org/10.1093/mr/roaf007
Vancouver
Takeuchi T, Pfeifer C, Zhong Y, Piao Y, Kaise T, Tani M. Real-world treatment persistence in csDMARD-IR and bDMARD-IR patients with rheumatoid arthritis in Japan: A large claims database study. Modern Rheumatology. 2025. doi:10.1093/mr/roaf007
BibTeX
@article{Takeuchi2025,
author = {Takeuchi, Tsutomu and Pfeifer, Craig and Zhong, Yan and Piao, Yi and Kaise, Toshihiko and Tani, Mahiro},
title = {Real-world treatment persistence in csDMARD-IR and bDMARD-IR patients with rheumatoid arthritis in Japan: A large claims database study},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roaf007}
}
EUVIMED